Clinical Trials Sponsored by UNICEF Jamaica

Total 5474 results

United Laboratories

Completed

Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos

Pediculosis Capitis

Philippines
United Therapeutics

Terminated

Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial Hypertension

Australia
United Therapeutics

Completed

ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Neuroblastoma

United States
United Pharmaceuticals

Completed

Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula (SONAR)

Gastroesophageal Reflux

Belgium, France
United Therapeutics

Withdrawn

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers

PAH

United States
Unimed Pharmaceuticals

Completed

A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome (UNCNT)

Menopausal Syndrome

Korea, Republic of
United Therapeutics

Terminated

Open-Label Study of Oral Treprostinil in Digital Ulcers (DISTOL-EXT)

Systemic Sclerosis

United States, Canada, United Kingdom
United Therapeutics

Terminated

A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients

Primary Refractory Neuroblastoma

United States
United Therapeutics

Completed

Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects

Pulmonary Arterial Hypertension

United States
United Therapeutics

Withdrawn

Safety and Efficacy of Inhaled Treprostinil in Patients With PAH (INTREPID)

Pulmonary Arterial Hypertension
United Therapeutics

Withdrawn

Inhaled Treprostinil for PAH: Open-label Extension (INTREPID - OL)

Pulmonary Arterial Hypertension
United Therapeutics

Completed

Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil

Pulmonary Arterial Hypertension | Hypertension, Pulmonary

United States
United BioPharma

Recruiting

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Taiwan
United Laboratories

Recruiting

Lactoferrin + Vitamin E + Zinc for Hormonal Acne

Hormonal Acne

Philippines
United Therapeutics

Recruiting

Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis (TETON)

Idiopathic Pulmonary Fibrosis | Interstitial Lung Disease

United States, Canada
United Therapeutics

Recruiting

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Cardiovascular Diseases | Vascular Diseases | Lung Diseases | Hypertension | Connective Tissue Diseases | Pulmonary Arterial Hypertension | Familial Primary Pulmonary Hypertension | Hypertension, Pulmonary | Pulmonary Hypertension | PAH | Respiratory Tract Disease

United States, Australia, Austria, Italy, Taiwan, Spain, Korea, Republic of, Canada, United Kingdom, Singapore, Argentina, Germany, France, Belgium, Mexico, Brazil, Hungary, Bulgaria, Chile, Czechia, Denmark, Greece, Israel, Netherlands, Pola... and more
United Therapeutics

Terminated

Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn

Persistent Pulmonary Hypertension of the Newborn

United States
United Therapeutics

Completed

Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso (BREEZE)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Terminated

Rapid Switch From Flolan to Remodulin in the Outpatient Clinic

Hypertension, Pulmonary

United States
United Therapeutics

Completed

A Pharmacokinetic Substudy of the TDE-PH-304 Protocol

Pulmonary Arterial Hypertension

United States
United Therapeutics

Terminated

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH) (TRIUMPH)

Pulmonary Hypertension

United States, Israel, Austria, United Kingdom, Belgium, France, Germany, Ireland, Italy, Spain
United Therapeutics

Completed

Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine (DISTOL-1)

Systemic Sclerosis | Scleroderma

United States, Canada, United Kingdom
United Pharmaceuticals

Active, not recruiting

Evaluation of an Adapted Formula on Atopic Dermatitis.

Atopic Dermatitis

Belgium, France
United Therapeutics

Active, not recruiting

ADAPT - A Patient Registry of the Real-world Use of Orenitram® (ADAPT)

Pulmonary Arterial Hypertension

United States
United BioPharma

Withdrawn

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

HIV-1 Infection

China
United Therapeutics

Completed

Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Australia, Bulgaria, Czechia, Hungary, Poland, Romania, Serbia, Slovakia, Spain
United Therapeutics

Terminated

A Safety Study of IV Stem Cell-derived Extracellular Vesicles (UNEX-42) in Preterm Neonates at High Risk for BPD

Bronchopulmonary Dysplasia

United States
United Therapeutics

Completed

Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Australia, Hungary, Bulgaria, Czechia, Poland, Romania, Serbia, Spain
United Therapeutics

Terminated

Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients

Neuroblastoma

United States
United Laboratories

Unknown

SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS

Tinea Pedis

Philippines
United Pharmaceuticals

Completed

Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula (ALYCE)

Cow Milk Allergy

Italy
United Pharmaceuticals

Completed

SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01) (SWAN)

Gastroesophageal Reflux

Belgium
United Therapeutics

Withdrawn

Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension
United Therapeutics

Completed

FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, United Kingdom, Canada, Spain, Australia, Israel, Germany, Belgium, France, Austria, Italy, Poland, Ireland, Netherlands
United Therapeutics

Withdrawn

Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH

Pulmonary Arterial Hypertension
United Therapeutics

Withdrawn

Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD

Chronic Obstructive Pulmonary Disease | Pulmonary Hypertension
United Therapeutics

Completed

A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension

Pulmonary Hypertension

United States
United Therapeutics

Completed

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies (Aspire)

Pulmonary Arterial Hypertension

United States
United Therapeutics

Completed

Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers (TDE-PH-125)

Healthy

United States
United Pharmaceuticals

Completed

Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy (COMETE)

Cow Milk Allergy

Italy, France, Belgium
United Therapeutics

Terminated

Effects of Remodulin in Patients With Critical Limb Ischemia Following a Vein Bypass Graft

Peripheral Vascular Disease

United States
United Therapeutics

Completed

A Transition Study From Flolan® to Remodulin® in Patients With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension | Pulmonary Hypertension

United States
United Therapeutics

Withdrawn

FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

Pulmonary Hypertension

United States, Australia, Mexico
United Therapeutics

Completed

Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension (FREEDOM-C2)

Pulmonary Hypertension

United States, Canada, Germany, Spain, Belgium, Sweden, Israel, France, Italy, Netherlands, Portugal, United Kingdom
United Therapeutics

Completed

Safety, Efficacy and Treatment Satisfaction in Patients With PAH Rapidly Switched From Epoprostenol to Remodulin

Pulmonary Hypertension

United States
United Therapeutics

Completed

Three Times Daily Dosing of UT-15C

Healthy

United States
United Therapeutics

Completed

Pharmacokinetics of Oral Treprostinil in Patients With Systemic Sclerosis (DISTOL-PK)

Systemic Sclerosis

United States
United Therapeutics

Completed

A Bioavailability Study Comparing Treprostinil Diethanolamine Oral Tablets and Oral Solution in Healthy Volunteers

Pulmonary Arterial Hypertension

United States
United Therapeutics

Terminated

Transitioning To IV Remodulin From Ventavis in Patients With PAH: Safety, Efficacy and Treatment Satisfaction

Hypertension, Pulmonary

United States

3

Subscribe